by H.S. AyoubBioHealth Investor.com Biotechnology ALFACELL CORP +30.34% VION PHARM INC +19.64% MEDIMMUNE INC +17.83% CURIS INC +14.45% XOMA LTD +11.71% Diagnostic Substances ISTA PHARMACTLS +9.44% THRESHOLD PHARMACEUT +3.35% ASPENBIO PHARMA INC +2.71% IMMUCELL…
From BioHealth Investor
Boston Scientific (BSX) reported that sales for the first quarter of 2007 were $2.086 billion as compared to $1.620 billion for the first quarter of 2006. EPS came in at $.08. Analysts surveyed by…
by H.S. AyoubBioHealth Investor.com
From BioHealth Investor
Pfizer (PFE) did not have a very good quarter. Net income fell from $4.1 billion in the comparable quarter a year ago to $3.4 billion in the recent quarter. The company confirmed that it…
by H.S. AyoubBioHealth Investor.com
Pfizer (PFE) reports on Friday, and just liketearing off a band-aid, investors are hoping the earnings release tobe quick, and relatively painless. Nobody’s expecting anythingspectacular on the “good news” front, while many issues both…
Merck (MRK) announced what the market expected. On that note, they are already ahead of Yahoo!. Revenue hit $5.8 billion up 7% for the quarter. EPS without restructuring costs, hit $.84, up from $.78…
by H.S. AyoubBioHealth Investor.com
We can see the sweat on their brow, but all in all Merck (MRK) is running a pretty good race these days going into Thursday’s earnings. With the recent pop from news that the…
by H.S. AyoubBioHealth Investor.com
by H.S. AyoubBioHealth Investor.com
GlaxoSmithKline (GSK-NYSE/ADR) has just announced more positive data on its cervical cancer vaccine called CERVARIX(R). The company has said that it demonstrated 100% protection against "HPV" (Human Papillomavirus-type 16 & 18) for precancerous lesions…
Cell Genesys, Inc. (CEGE-NASDAQ) is trading up more than 7% at $5.50 in earlybird trading on thin volume this morning on its new prostate cancer studies. Yesterday it closed down at $5.10, more than…